Illumina Target of Unusually Large Options Trading (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) saw unusually large options trading on Tuesday. Investors purchased 6,321 put options on the stock. This represents an increase of 50% compared to the average daily volume of 4,204 put options.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research report on Thursday, January 4th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and set a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Finally, HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus target price of $167.70.

Illumina Trading Down 2.1 %

NASDAQ ILMN traded down $2.57 during trading on Tuesday, hitting $118.59. The company had a trading volume of 383,010 shares, compared to its average volume of 1,742,006. The company’s fifty day moving average is $135.35 and its 200-day moving average is $128.35. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. Illumina has a one year low of $89.00 and a one year high of $232.23.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the company earned $0.14 earnings per share. The business’s revenue was up 3.6% compared to the same quarter last year. Equities research analysts expect that Illumina will post 0.91 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently bought and sold shares of the company. LM Advisors LLC bought a new position in shares of Illumina in the fourth quarter worth approximately $28,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in Illumina in the 3rd quarter valued at approximately $30,000. State of Wyoming purchased a new stake in Illumina during the 2nd quarter valued at $32,000. Quent Capital LLC increased its holdings in shares of Illumina by 71.2% in the 3rd quarter. Quent Capital LLC now owns 250 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 104 shares in the last quarter. Finally, VisionPoint Advisory Group LLC increased its holdings in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.